Frovatriptan

CNS Drugs

Volumn 15, Issue 12, 2001, Pages 969-976

  Easthope, Stephanie E ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FROVATRIPTAN; PLACEBO; SEROTONIN 1B AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR;

BASILAR ARTERY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FATIGUE; HUMAN; MIGRAINE; NAUSEA; PARESTHESIA; PHARMACODYNAMICS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW;

EID: 0035667312     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115120-00006     Document Type: Review

References (5)

1. Lipton RB, Stewart WE The epidemiology of migraine. Eur Neurol 1994; 34 Suppl. 2: 6-11
2. Diener H-C, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998 Nov; 56 (5): 811-24
3. Goadsby PJ, Olesen J. Diagnosis and management of migraine. BMJ 1996 May 18; 312: 1279-83
4. 1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997; 17: 833-42
5. 1D receptors [abstract]. Br J Pharmacol 1996 Oct; 119 Proc Suppl.: 110P